Docetaxel–Cabazitaxel–Enzalutamide Versus Docetaxel–Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer
Authors:
I. Richter 1,2; J. Dvořák 2
; J. Bartoš 1
Authors place of work:
Onkologické oddělení, Krajská nemocnice Liberec, a. s.
1; Onkologická klinika 1. LF UK a Thomayerova nemocnice, Praha
2
Published in the journal:
Klin Onkol 2017; 30(4): 289-293
Category:
Original Articles
doi:
https://doi.org/10.14735/amko2017289
Summary
Aim:
The aim of this retrospective study was to compare the efficacy of the sequence docetaxel–cabazitaxel–enzalutamide vs. docetaxel–enzalutamide in patients with metastatic castration-resistant prostate cancer.
Patients and Methods:
Of the cohort of 35 patients, 11 were treated with the sequence docetaxel–cabazitaxel–enzalutamide and 24 were treated with the sequence docetaxel–enzalutamide. The doses were as follows: docetaxel, 75 mg/m2; cabazitaxel, 25 mg/m2; and enzalutamide, 160 mg/day. Overall survival (OS) was defined as the interval between the initial dose of docetaxel and death or the date of the last control for survivors (censored). OS was assessed using the Kaplan-Meier method, and the two arms were compared using the log-rank test. The significance level for all statistical tests was set at α = 0.05.
Results:
The median OS of patients treated with the sequence docetaxel–cabazitaxel–enzalutamide was 28.8 months, vs. 24.4 months in patients treated with the sequence docetaxel–enzalutamide. No statistically significance differences in OS were found between the two arms (HR 0.678, 95% CI 0.264–1.744; p = 0.418). Grade 3–4 toxicity was observed for each drug, as follows: docetaxel: fatigue and peripheral neuropathy in six patients, nausea in three patients, and diarrhea and neutropenia in one patient; cabazitaxel: anemia in two patients and neutropenia in one patient; and enzalutamide: anemia in six patients, thrombocytopenia in two patients, and cerebral hemorrhage in one patient.
Conclusion:
No statistically significant differences in OS were found between the sequences docetaxel–cabazitaxel–enzalutamide and docetaxel–enzalutamide.
Key words:
prostate cancer – metastasis – chemotherapy – targeted hormonal treatment
The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.
The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.
Submitted:
13. 2. 2017
Accepted:
20. 3. 2017
Zdroje
1. Ondrušová M, Mužík J, Kliment J et al. Prostate cancer incidence and mortality in selected countries of central Europe. Klin Onkol 2011; 24 (2): 126–132.
2. Mottet N, Bastian PJ, Bellmunt J et al. EAU Guidelines on Prostate Cancer – update April 2014. Arnhem: European Association of Urology 2014: 172.
3. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantron plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351 (15): 1502–1512.
4. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone plus prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351 (15): 1513–1520.
5. Katolická J. Chemoterapie v léčbě kastračně rezistentního karcinomu prostaty. Urol Praxi 2014; 15 (3): 120–122.
6. Ondruš D, Ondrušová M. Manažement pacientov s kastračne rezistentným metastatickým karcinómom prostaty. Klin Onkol 2015; 28 (1): 24–29. doi: 10.14735/amko201524.
7. Richter I, Dvořák j, Bartoš J. Možnosti chemoterapie v léčbě karcinomu prostaty. Klin Onkol 2017; 30 (1): 28–33. doi: 10.14735/amko201728.
8. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostatae cancer progressing after docetaxel treatment: a randimised open-label trial. Lancet 2010; 376 (9747): 1147–1154. doi: 10.1016/S0140-6736 (10) 61389-X.
9. Sartor AO. Progression of metastatic castrate-resistant prostatae cancer: impact of therapeutic intervention in the post-docetaxel space. J Hematol Oncol 2011; 4: 18. doi: 10.1186/1756-8722-4-18.
10. Chen CD, Welsbie DS, Tran C et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2003; 10 (1): 33–39.
11. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer directed therapies targeting the androgen-receptor signaling axil. J Clin Oncol 2005; 23 (32): 8253–8261.
12. Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367 (13): 1187–1197.
13. Richter I, Dvořák J, Hejzlarová V et al. Enzalutamid a abirateron v léčbě metastatického kastračně refrakterního karcinomu prostaty po předchozí chemoterapii. Klin Onkol 2016; 29 (2): 127–132. doi: 10.14735/amko2016127.
14. Richter I, Dvořák J, Hejzlarová V et al. Kabazitaxel v léčbě metastatického kastračně rezistentního karcinomu prostaty. Ces Urol 2016; 20 (3): 198–204.
15. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 2006; 24 (10): 1633–1642.
16. Tsao CK, Cutting E, Martin J et al. The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer. Ther Adv Urol 2014; 6 (3): 97–104. doi: 10.1177/1756287214528557.
17. Heidenreich A, Bracarda S, Mason M et al. Safety of cabazitaxel in senior adults with metastatic castration-resistant prostatae cancer: results of the European compassionate-use programme. Eur J Cancer 2014; 50 (6): 1090–1099. doi: 10.1016/j.ejca.2014.01.006.
18. Richter I, Dvořák J, Bartoš J. Enzalutamid v postchemo indikaci. 24. onkologicko-urologické sympózium, Praha, 24. 11. 2016.
19. van Soest FJ, van Royen ME, de Morree ES et al. Cross-resistance between taxanes and new hormonal agents abirateron and enzalutamide may affect drug semence choices in metastatic castration-resistant prostate cancer. Eur J Cancer 2013; 49 (18): 3821–3830. doi: 10.1016/ j.ejca.2013.09.026.
20. Pezaro CJ, Le Moulec S, Albiges L et al. Response to cabazitaxel in CRPC patients previously treated with docetaxel and abirateron acetate. J Clin Oncol 2013; 31 (Suppl 6): abstr. 155.
21. Wissing MD, Coenen JL, Van den Berg P et al. A retrospective study on cabazitaxel and abirateron acetate sequential treatment (CAST) in docetaxel treated metastatic castrate-resistant prostate cancer patients. Eur Cancer Congr 2013; 411: abstr. 2904.
22. Oudard S, Angelergues A, Efstathiou E et al. Updated results of the FLAC European diabase of metastatic castration resistant prostate cancer (mCRPC) patients (pts) treated with life extending therapies in post-docetaxel (D) petting. Eur J Cancer 2015; 51 (Suppl 3): S489. abstr. 2541.
23. Ryan CJ, Smith MR, de Bono JS et al. Abirateron in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368 (2): 138–148. doi: 10.1056/ NEJMoa1209096.
24. Beer TM, Amstrong AJ, Rathkof DE et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371 (5): 424–433. doi: 10.1056/NEJM-oa1405095.
25. Mezynski J, Pezaro C, Bianchini D et al. Antitumour aktivity of docetaxel following treatment with the CYP17A1 inhibitor abirateron: clinical evidence for cross-resistence? Ann Oncol 2012; 23 (11): 2943–1947. doi: 10.1093/annonc/mds119.
26. Darshan MS, Loftus MS, Thadani-Mulero M et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical response in metastatic prostate cancer. Cancer Res 2011; 71 (18): 6019–6029. doi: 10.1158/0008-5472.CAN-11-1417.
27. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rew Cancer 2004; 4 (4): 253–265.
28. Moos PJ, Fritzpatrick FA. Taxane propagate apoptosis via two cell populations with distinctive cytological traits. Cell Growth Differ 1998; 9 (8): 687–697.
29. Li Y, Li X, Hussain M et al. Regulation of mikrotubul, apoptosis, and cell cycle-related genes by Taxotere in prostate cancer cells analyzed by microarray. Neoplasia 2004; 6 (2): 158–167.
30. van Soest RJ, van Royen ME, de Morree ES et al. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamid may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur J Cancer 2013; 49 (18): 3821–3830. doi: 10.1016/ j.ejca.2013.09.026.
31. de Bono JS, Logothesis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364 (21): 1995–2005. doi: 10.1056/ NEJMoa1014618.
32. Templeton AJ, Ver-Badillo FE, Wang L et al. Translating clinical trials to clinical practice: outsomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Ann Oncol 2013; 24: 2942–2977.
Štítky
Paediatric clinical oncology Surgery Clinical oncologyČlánok vyšiel v časopise
Clinical Oncology
2017 Číslo 4
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Current Insights into the Antispasmodic and Analgesic Effects of Metamizole on the Gastrointestinal Tract
- Obstacle Called Vasospasm: Which Solution Is Most Effective in Microsurgery and How to Pharmacologically Assist It?
- Spasmolytic Effect of Metamizole
- Metamizole in perioperative treatment in children under 14 years – results of a questionnaire survey from practice
Najčítanejšie v tomto čísle
- Reactive Lymphoid Hyperplasia of the Liver
- Metastatic Pituitary Disorders
- Radiotherapy of Lung Tumours in Idiopathic Pulmonary Fibrosis
- Radiation Necrosis in the Upper Cervical Spinal Cord in a Patient Treated with Proton Therapy after Radical Resection of the Fourth Ventricle Ependymoma